FDA REFORM BILL FOCUSING ON THIRD PARTY REVIEW PLANNED BY HOUSE "BLUE DOGS"; OVERSIGHT SUBCMTE. HEARING ON COMMISSIONER's OFFICE PLANNED FOR FEBRUARY
An FDA reform proposal under development by the House Democratic "Blue Dog" coalition is understood to be focusing on third-party reviews.The coalition bill likely would avoid controversial elements such as permitting off-label information dissemination and imposing "hammers" if the agency failed to meet performance goals.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth